Novo Nordisk to test app and heart disease antibody in phase III trial
Next year, Novo Nordisk may very well be able to initiate a phase III trial of antibody ziltivekimab, which stems from the multimillion-dollar acquisition of US-based Corvidia Therapeutics, alongside an app.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to launch sought-after obesity drug in Denmark
For subscribers